Recent articles from Anastasiia
10 Companies Shaping the Brain-Computer Interface Landscape: Invasive vs Non-Invasive BCI Technology
The brain–computer interface (BCI) technology domain is constantly progressing as researchers and companies collaborate to devise inventive solutions that connect the human brain with external devices. This expanding sector, driven by the need for better communication, rehabilitation, and augmented cognitive …
9 Companies Using Artificial Intelligence to Fight Infectious Diseases
Development of a novel drug is a tedious process that requires immense investments of resources and time—on average, it takes from 8-10 years and capitalized R&D costs are reported between ~$1.1B median and ~$2.2B+ per asset in large-pharma cohorts for …
Ginkgo Bioworks Launches Open-Source Pharmacology Framework for AI Drug Discovery
Ginkgo Bioworks has introduced the Virtual Cell Pharmacology Initiative (VCPI) through its Ginkgo Datapoints division, creating what it describes as the first open-source pharmacological framework for virtual cell modeling. The effort aims to establish a standardized foundation for AI-based drug …
Antheia and TAPI Announce Strategic Partnership to Scale Biosynthetic Pharmaceutical Manufacturing
Antheia and TAPI have formed a strategic partnership to accelerate global commercialization of Antheia’s biosynthetic manufacturing platform for key starting materials (KSMs) and active pharmaceutical ingredients (APIs). The collaboration integrates Antheia’s synthetic biology and fermentation-based production technology with TAPI’s …
Terray Launches Experiment-Driven Machine Learning Platform for Small-Molecule Discovery
Terray Therapeutics introduced EMMI—Experimentation Meets Machine Learning—as an integrated platform that pairs ultra-dense microarray experimentation with a full AI stack used daily across its discovery programs. The company reports more than 13 billion proprietary compound-target measurements generated …
Five Companies Leading the Way in 3D Bioprinting
Lately, bioprinting is shifting from proof-of-concept prints to regulated workflows and early clinical use. In July 2022 in San Antonio, Texas, surgeons performed the first human ear reconstruction using a patient-matched, 3D-bioprinted living tissue implant—developed by PrintBio (formerly 3DBio …
Roche and Manifold Bio's up-to-$2B Deal to Develop Next-Gen Brain Shuttles for Neurological Diseases
Manifold Bio, a Boston-based platform therapeutics company, announced a strategic collaboration and license agreement with Roche to develop several next-generation blood-brain barrier (BBB) shuttles intended for neurological and neurodegenerative disease programs. The work will apply Manifold’s tissue-targeting shuttle portfolio …
7 Biotechs Fighting Rare Diseases With Gene-Editing Tech
Rare diseases sit at an uncomfortable scale: about 30 million people in the U.S., roughly >300 million worldwide. According to NIH, there are an estimated 6,000 to 8,000 rare diseases, though the exact number is continually changing as new …
New AI Reportedly Surpasses AlphaFold 3 in Drug-Protein Binding Prediction
Genesis Molecular AI, in collaboration with NVIDIA, has announced a generative 3D foundation model for protein–ligand structure prediction, Pearl (Placing Every Atom in the Right Location). Genesis reports state-of-the-art results on public benchmarks …
7 Notable Companies Advancing Women’s Health with AI
Back in 2016, Ida Tin, the CEO behind the renowned period-tracking app Clue, introduced the term "FemTech" to capture the wave of startups pushing the boundaries of technology in the realm of female health. Today, the term encompasses an even …